数字药店 Hims & Hers Health 推出 GLP-1 减肥注射剂，解决了诺和诺德主导的市场供应问题。 Digital pharmacy Hims & Hers Health launches GLP-1 injections for weight loss, addressing market supply issues dominated by Novo Nordisk.

数字药店初创公司 Hims & Hers Health 通过复合 GLP-1 注射剂扩展其减肥计划，解决了由诺和诺德的 Ozempic 和 Wegovy 主导的市场供应问题。 Digital pharmacy startup Hims & Hers Health expands its weight loss program with compounded GLP-1 injections, addressing supply issues in the market dominated by Novo Nordisk's Ozempic and Wegovy. 该公司与一家大型仿制药制造商合作以获得稳定的供应，并以每月 199 美元的价格提供注射剂，并计划在品牌药物上市后推出。 The company partners with a large generic manufacturer for a consistent supply and offers the injections starting at $199 per month, with plans to introduce branded options once available.